Copenhagen, 18 August 2010 - The NeuroSearch A/S (NEUR) H1 interim report for
2010 will be on the agenda of a Board meeting scheduled for 25 August 2010 and
will be released immediately hereafter.
The H1 interim report will be presented at a telephone conference on the same
day at 15:00 pm Copenhagen time (14 pm London time, 9 am New York time).
Participating in the conference will be CEO Flemming Pedersen, Vice President &
CFO Anita Milland and Vice President and Director of Investor & Capital Market
Relations Hanne Leth Hillman. The telephone conference will be conducted in
English and the dial-in numbers are: UK and International +44 207 509 5139, US
+1 718 354 1226, and DK +45 3271 4767.
Contact person:
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103
About NeuroSearch - Company profile
NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical
company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business
is development of novel drugs to treat diseases of the central nervous system,
and the pipeline comprises eight products in clinical development (Phase
I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase
III development for the treatment of Huntington's disease, and tesofensine
ready for Phase III development as a novel treatment of obesity.
NeuroSearch is founded on a well-established drug discovery platform in the
field of small molecule pharmacology, ion channels and monoamine transporters,
leading to the continuous production of novel preclinical development
candidates. The company has strategic drug discovery alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
Further, NeuroSearch has equity interests in a number of private health care
companies.
